We applied LM22 to a publicly available dataset (GSE298325 (link)) to measure stability of deconvolution results over defined levels of blood admixed with breast tissue. To confirm reported fractions of blood admixed with breast tissue, we compared these proportions with an ‘LM22 normalized immune index’, defined for each sample as the median gene expression value of all genes in LM22 (Supplementary Table 1) divided by the median expression level of the transcriptome, and normalized into the range of known leukocyte content across the datasets (Fig. 2e). As a consistency metric, we compared deconvolution results for each sample with results from the sample with highest immune purity (Fig. 2e).